s6y

Liminatus Pharma, Inc.

Ticker
LIMN, LIMNW
CIK
1971387
Industry
Biological Products, (No Diagnostic Substances)
Formerly
Iris Parent Holding Corp.

Financials 9

  1. NT 10-Q Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. NT 10-Q Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB for period ending Jun 30, 2025
  8. 10-Q Quarterly Report for period ending Mar 31, 2025
  9. NT 10-Q Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB for period ending Mar 31, 2025

News 27

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 27 news filings

Ownership 16

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 3 Initial statement of beneficial ownership of securities
  4. 3 Initial statement of beneficial ownership of securities
  5. 3 Initial statement of beneficial ownership of securities
  6. 3 Initial statement of beneficial ownership of securities
  7. 3 Initial statement of beneficial ownership of securities
  8. 3 Initial statement of beneficial ownership of securities
  9. 3 Initial statement of beneficial ownership of securities
  10. 3 Initial statement of beneficial ownership of securities

All 16 ownership filings

Prospectus 17

  1. S-1 General form of registration statement for all companies including face-amount certificate companies
  2. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  3. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  4. S-1 General form of registration statement for all companies including face-amount certificate companies
  5. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. S-1/A General form of registration statement for all companies including face-amount certificate companies
  8. S-1 General form of registration statement for all companies including face-amount certificate companies
  9. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  10. 424B3 Prospectus filed pursuant to Rule 424(b)(3)

All 17 prospectus filings

Proxies 2

  1. DEF 14A Definitive proxy statements
  2. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

Other 40

  1. SCHEDULE 13G
  2. SCHEDULE 13D/A
  3. SCHEDULE 13G/A
  4. D Exempt (Private) Offering
  5. SCHEDULE 13G
  6. EFFECT Notice of Effectiveness
  7. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  8. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  9. UPLOAD Letter (PDF)
  10. EFFECT Notice of Effectiveness

All 40 other filings